Beryl Drugs Ltd — Updates, 12-04-2025: Company Update

Beryl Drugs has announced a board meeting to discuss the non-applicability of the Annual Secretarial Compliance Report for the financial year ending March 31, 2025. The company claims exemption under Regulation 15(2) of SEBI regulations, stating that it qualifies as a listed entity with a paid-up equity share capital below ₹10 crore and a net worth under ₹25 crore. This exemption allows the company to avoid submitting the compliance report, potentially reducing administrative burdens. Investors may view this as a neutral impact, reflecting the company's operational streamlining but also posing questions about its governance practices.